

- **TITOLO:** Immunotherapy Bridge
- **Data di svolgimento:** 30 novembre - 1 dicembre 2026
- **Sede di svolgimento dell'Evento:** Royal Continental Hotel (Via Partenope 38-42 – 80121 Napoli)
- **Tipologia:** RESIDENZIALE
- **Nome Segreteria Organizzativa:** VIVENKO Srl Società Benefit
- **Lingua:** INGLESE – non prevista traduzione

RAZIONALE SCIENTIFICO

Over the last years, an extensive research has improved our understanding of tumor immunology and enabled the development of novel treatments that can harness the patient's immune system and prevent immune escape.

Through numerous clinical trials and real-world experience, a large amount of evidence of the potential for long-term survival with immunotherapy agents has been accumulated in various types of malignancy, starting from melanoma to extend to other tumors.

The results of these studies have also highlighted a number of recurring observations with immuno-oncology agents, including their potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The clinical success of immune checkpoint blockade with anti-cytotoxic T-lymphocyte associated antigen (CTLA)-4 and anti-programmed death (PD)-1/PD-ligand (L)1 inhibitor in melanoma and other cancers has encouraged increasing development of other immunotherapies, particularly monoclonal antibodies with other immune targets, adoptive cell transfer and vaccines. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Study results have highlighted a number of recurring observations, including the immunotherapy potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The successes of the immune-oncology is strongly correlated with the immune system ability of "memory" and adaptability, to improve the time of survival and without selecting resistant form of tumoral cells. Another advantage is that the efficacy of immunotherapy drugs does not seem to be particularly influenced by histology and mutations.

The Immunotherapy Bridge will start with a Session jointly organized with SITC on modulator of Tumor Immunity and Immunotherapy.

Hence, we will discuss the state of the art of immunotherapy, novel drug development and novel approaches to cancer therapy, the last update on cancer vaccines and AI and then the organ specific immune response to share what different cancers teach about the general understanding of malignancies.

The final session will be focused on neoadjuvant therapies across cancers.

Immunotherapy Bridge will end with the Great Debate Sessions, in which the most important issues from clinical practice and research will be shown and exhaustively discussed from two different points of view.



PROGRAMMA SCIENTIFICO

****attività non inclusa nell'accREDITamento ECM**

30 novembre 2026

10.00 Introduction and Objectives, *Paolo A. Ascierto*

SITC SESSION - Modulator of Tumor Immunity and Immunotherapy

Chairpersons: James L. Gulley, Michael T. Lotze

10.10 Barriers to CAR T cells effectiveness, *Marco Ruella*

10.25 Q&A

10.30 Microbiome update, *Luigi Nezi*

10.45 Q&A

10.50 Systemic vs Local Metabolism, *Greg M. Delgoffe*

11.05 Q&A

11.10 Effects of aging and Immunity, *Leisha A. Emens*

11.25 Q&A

11.30 Nerves and Immune Cells, *Christine Moussion*

11.45 Q&A

11.50 The best of SITC 2026. *Paolo A. Ascierto*

12.10 Q&A

GREAT DEBATE

Chairpersons: Paolo A. Ascierto, Bernard A. Fox, James L. Gulley, Igor Puzanov

12.15 Fecal Transfer vs Diet, *Luigi Nezi VS Jennifer McQuade*

12.40 GLP1 is just weight loss: yes or no, *Jennifer Wargo VS Janis Taube*

13.05 The synergy medical nutrition drugs to improve therapy outcomes in oncology patients,
Maurizio Muscaritoli

13.25 Lunch**

SESSION 2 - NOVEL DRUG DEVELOPMENT and NOVEL APPROACHES TO CANCER THERAPY

Chairpersons: Alfredo Budillon, Luigi Buonaguro

14.15 Bispecific Antibodies, *James L. Gulley*

14.30 ADCs: Novel targets and novel payloads, *Leisha A. Emens*

14.45 NK Cells, *Andreas Lundqvist*

15.00 Radio Ligands, *Martina Benešová-Schäfer*

15.15 Cytokines, *Howard Kaufman*

15.30 Radiation as immunomodulating modality, *Sandra Demaria*

15.45 DISCUSSION ON NOVEL DRUGS DEVELOPMENT and NOVEL APPROACHES TO CANCER THERAPY



16.15 Coffee Break**

SESSION 3 – CANCER VACCINES AND AI

Chairpersons: *Bernard A. Fox, Catherine Wu*

- 16.30 The Dark Matter, *Bernard A. Fox*
- 16.45 mRNA Vaccines, *Paolo A. Ascierto*
- 17.00 Peptide Vaccines, *Catherine Wu*
- 17.15 US NCI national roadmap for cancer vaccines, *Stacey Adam*
- 17.30 Shared Antigens, *Craig Slingluff Jr.*
- 17.45 AI, *Carlo Bifulco*
- 18.00 DISCUSSION ON CANCER VACCINES AND AI

1 dicembre 2026

SESSION 4 - ORGAN SPECIFIC IMMUNE RESPONSE

Chairpersons: *Omid Hamid, Samir Khleif*

- 09.15 Pancreatic Cancer, *Gregory Lesinski*
- 09.30 Colon Cancer, *Myriam Chalabi*
- 09.45 RCC, *Toni Choueiri*
- 10.00 Bladder, *Bradley McGregor*
- 10.15 Brain, *Hussein Tawbi*
- 10.30 Ovarian, *Kunle Odunsi*
- 10.45 Prostate, *Matthew Dallos*
- 11.00 DISCUSSION ON ORGAN SPECIFIC IMMUNE RESPONSE

11.15 Coffee Break**

GREAT DEBATE

Chairpersons: *Paolo A. Ascierto, Bernard A. Fox, James L. Gulley, Igor Puzanov*

- 11.30 Models: pro/cons of animal vs human, *Chrystal Paulos vs Bernard Fox*
- 11.55 CD4 vs CD8 Effector Cells, *Chrystal Paulos VS Pedro Romero*
- 12.20 Macrophages vs CAF, *Mikael Pittet VS Fatima Mechta-Grigoriou*

12.45 LECTURE - Immunotherapy in the early stages: perioperative management across cancers

Head & Neck, *Paolo Bossi*

Lung, *Tina Cascone*

13.15 Lunch++



14.10 SYMPOSIUM – Non-Melanoma Skin Cancers

The treatment of CSCC and BCC: an update

Paolo A. Ascierto, Dirk Schadendorf

SESSION 5 - NEOADJUVANT THERAPY ACROSS CANCERS

Chairpersons: *Paolo A. Ascierto, Elizabeth M. Burton*

15.00 INNOVATE summary, *Paolo A. Ascierto*

15.15 Breast, *Marleen Kok*

15.30 Lung, *Tina Cascone*

15.45 Melanoma, *Christian Blank*

16.00 Non-Melanoma Skin Cancers, BCC and CSCC, *Neil D. Gross*

16.15 Histology agnostic neoadjuvant trials, *Myriam Chalabi*

16.30 Pan-tumor path response assessment, *Julie Stein Deutsch*

16.45 DISCUSSION on NEOADJUVANT THERAPY ACROSS CANCERS

17.15 **Conclusion**, *Paolo A. Ascierto, Bernard A. Fox, James Gulley, Igor Puzanov*

QUALIFICHE PROFESSIONALI E SCIENTIFICHE DEL RESPONSABILE SCIENTIFICO E DEI RELATORI:

COGNOME	NOME	LAUREA	SPECIALIZZAZIONE	AFFILIAZIONE
Ascierto	Paolo Antonio	Medicina e Chirurgia	Oncologia	Full professor of Oncology; Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Department, University of Naples Federico II; National Cancer Institute "Fondazione G. Pascale", Naples
Adam	Stacey	Biochimica	Farmacologia e Tossicologia	Senior Vice President, Chief Clinical Officer, FNIH - Foundation for the National Institutes of Cancer
Benešova Schäfer	Martina	Chimica	Chimica nucleare e radiofarmaceutica	Group Head, Translational Radiotheranostics, DKFZ German Cancer Research Center, Heidelberg, Germany
Bifulco	Carlo	Medicina e Chirurgia	Anatomia Patologica	Medical Director of Oncological Molecular Pathology and pathology Informatics, Providence Oregon Regional Laboratory, Director of Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute
Blank	Christian	Medicina e Chirurgia	Oncologia, Ematologia	Director of Sarcoma and Melanoma Program; Medical Oncology and Research Group Leader Tumor Immunology, IEO, European Oncology Institut; Netherlands Cancer Institute



Bossi	Paolo	Medicina e Chirurgia	Oncologia	Capo Sezione, Oncologia medica - Tumori Testa-Collo E Tumori Della Pelle Spinocellulari E Basocellulari, IRCCS Humanitas Research Hospital
Budillon	Alfredo	Medicina e Chirurgia	Radioterapia Oncologica	Scientific Director, National Cancer Institute "Fondazione G. Pascale", Naples
Buonaguro	Luigi	Medicina e Chirurgia	Microbiologia e Virologia	Director, Innovative Immunological Models Unit, National Cancer Institute "Fondazione G. Pascale" Naples
Burton	Elizabeth M.	Genetica	//	Director, Research Planning & Development, Surgical Oncology
Cascone	Tina	Medicina e Chirurgia	Medicina Interna, Oncologia	Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Chalabi	Myriam	Medicina e Chirurgia	Oncologia	Medical Oncologist, GI cancers, Netherlands Cancer Institute (NKI)
Choueiri	Toni K.	Medicina e Chirurgia	Oncologia; Medicina Interna	Director of the Lank Center for Genitourinary (GU) Oncology; co-leader of the Kidney Cancer Program; Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School
Dallos	Matthew	Medicina e Chirurgia	Oncologia	Assistant Attending Physician, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center
Delgoffe	Greg M.	Medicina e Chirurgia	Immunologia	Director, Graduate Program in Microbiology and Immunology (PMI); Professor, Department of Immunology; Associate Director of Basic Research
Demaria	Sandra	Medicina e Chirurgia	Anatomia Patologica	Professor Pathology and Laboratory Medicine, Professor of Radiation Oncology, Weill Cornell Medical College
Deutch	Julie Stein	Medicina e Chirurgia	Pathology	Assistant Professor of Dermatology and Oncology, The Johns Hopkins University School of Medicine
Emens	Leisha A.	Medicina e Chirurgia	Oncologia	Senior Vice President Translational Research; President of Society for Immunotherapy of Cancer (SITC), Ankyra Therapeutics; Society for Immunotherapy of Cancer (SITC)
Fox	Bernard A.	Medicina e chirurgia	Immunologia	Chief of Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center
Gross	Neil D.	Medicina; Biologia	Chirurgia Generale	Director Clinical Research, Department of Head and Neck Surgery, The University of Texas, MD Anderson Cancer Center
Gulley	James L.	Medicina e Chirurgia	Oncologia; Medicina Interna	Co-Director of the Center for Immuno-Oncology; President of Society for Immunotherapy of Cancer (SITC)



Hamid	Omid	Medicina e Chirurgia	Oncologia	Chief of Research/Immuno-Oncology: Co-Director Cutaneous Malignancy Program
Kaufman	Howard	Medicina e Chirurgia	Chirurgia Generale; Immunologia	Surgical Oncologist, Massachusetts Eye and Ear Hospital; Massachusetts General Hospital
Khleif	Samir N.	Medicina e Chirurgia	Oncologia; Medicina Interna	Director of the Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center
Kok	Marleen	Medicina e Chirurgia	Oncologia	Senior Group Leader, Department of Tumor Biology and Immunology, Netherlands Cancer Institute
Lesinski	Gregory B	Scienze Biomediche	–	Professor, Vice Chair for Basic Research, Department of Hematology & Medical Oncology Associate Director for Basic Research Co-Director, Translational GI Malignancy Program
Lotze	Michael T.	Medicina e Chirurgia	Immunologia	Professor of Surgery, Immunology, and Bioengineering, University of Pittsburgh School of Medicine
Lundqvist	Andreas	Medicina e Chirurgia	Oncologia	Professor of Oncological Immunotherapy, Department of Oncology-Pathology, Karolinska Institutet
McGregor	Bradley	Medicina e Chirurgia	Oncologia	Director of Clinical Research, Lank Center for Genitourinary Oncology – Assistant Professor of Medicine
Mechta Grigoriou	Fatima	Scienze	Cancer Biology	Directrice de Recherche de Classe Exceptionnelle; Directrice de l'équipe "Stress et Cancer"
Mc Quade	Jennifer L.	Medicina e Chirurgia	Oncologia	Associate Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine
Moussion	Christine	Medicina e Chirurgia	Immunologia	Research Group Leader, Cancer Immunology, Genentech, South San Francisco, CA, USA
Muscaritoli	Maurizio	Medicina e Chirurgia	Nefrologia; Medicina Interna	Professore Ordinario Medicina Interna; Laboratorio di Ricerca Traslazionale in Nutrizione e Metabolismo, Sapienza Università di Roma
Nezi	Luigi	Biotechnologia	Biotechnologie mediche	Ricercatore e Group Leader Microbiome e Antitumor Immunity, IEO Istituto Europeo di Oncologia
Odunsi	Adekunle	Medicina e Chirurgia	Oncologia	Director, University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, US
Paulos	Chrystal M.	Biochimica	Immunologia	Director of translational research in cutaneous malignancies; Associate Professor, Department of Surgery, Department of Microbiology and Immunology
Pittet	Mikael	Medicina e Chirurgia	immunologia	Full Professor, Department of Pathology and Immunology; ISREC Foundation Chair in Immuno-Oncology, University of Geneva



Puzanov	Igor	Medicina e Chirurgia	Immunologia, Medicina Interna	Professor of Medicine and Oncology, Director Early Phase Clinical Trials Program, Co-Leader Experimental Therapeutics Program, Chief Melanoma Section
Romero	Pedro	Medicina e Chirurgia	Immunologia	Full Professor, University of Lausanne, Suisse
Ruella	Marco	Medicina e Chirurgia	Ematologia	Associate Professor of Medicine (Hematology-Oncology); Scientific Director of Lymphoma Program, University of Pennsylvania; Abramson Cancer Center
Schadendorf	Dirk	Medicina e Chirurgia	Dermatologia e Venereologia, Allergologia ed Immunologia Clinica	Director of Clinic for Dermatology, University Hospital Essen, Germany
Slingluff	Craig Jr	Medicina e chirurgia	Immunologia; Oncologia	Professor of Surgery, Division of Surgical Oncology, Breast and Melanoma Surgery; Director, Human Immune Therapy Center
Taube	Janis M.	Medicina e Chirurgia	Pathology	Professor of Dermatology and Pathology; Director, Division of Dermatopathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Tawbi	Hussein	Medicina e Chirurgia	Oncologia; Medicina Interna	Deputy Chair and Director of Personalized Cancer Therapy, Department of Melanoma Medical Oncology, Division of Cancer Medicine; Co-Director
Wargo	Jennifer	Medicina e Chirurgia	Chirurgia Generale	Professor of Surgical Oncology and Genomic Medicine; Deputy Director, University of Texas MD Anderson Cancer Center, Houston, TX, US
Wu	Catherine	Medicina e Chirurgia	Biochimica	Chief, Division of Stem Cell Transplantation and Cellular Therapies; Lavine Family Chair for Preventative Cancer Therapies, Dana-Farber Cancer Institute, Boston, MA, US

Responsabile Scientifico dell'evento: Paolo A. Ascierto | Professore Ordinario di Oncologia, Università degli Studi di Napoli Federico II; Direttore Struttura Complessa Oncologia Sperimentale, Melanoma, Immunoterapia e Terapie Innovative, Istituto Nazionale dei Tumori IRCCS Fondazione G. Pascale, Napoli

DESTINATARI:

- **Farmacista** (Farmacista pubblico del SSN; Farmacia Ospedaliera; Farmacista di altro settore);
- **Medico Chirurgo** (Allergologia ed immunologia clinica; dermatologia e venereologia; ematologia; gastroenterologia ed endoscopia digestiva; Malattie dell'apparato respiratorio; medicina interna; nefrologia; neurologia; oncologia; radioterapia; chirurgia generale; chirurgia plastica e ricostruttiva; ginecologia e ostetricia; urologia; anatomia patologica; farmacologia e tossicologia clinica; laboratorio di genetica medica; medicina nucleare; patologia clinica (laboratorio di analisi chimico-



cliniche e microbiologia); radiodiagnostica; igiene, epidemiologia e sanità pubblica; medicina generale (medici di famiglia); Scienza dell'alimentazione e dietetica; cure palliative);

ACRONIMI:

ADCs: Antibody-Drug Conjugate

AI: Artificial Intelligence

BCC: Basal Cell Carcinoma

CAF: Cancer-Associated Fibroblasts

CAR T: Chimeric Antigen Receptor T-cell

CD4: Cluster of Differentiation 4 (Linfociti T CD4)

CD8: Cluster of Differentiation 8 (Linfociti T CD8)

CSCC: Carcinoma a Cellule Squamose Cutaneo

GLP1: Glucagon-Like Peptide-1

NK: Natural Killer

mRNA: m RiboNucleic Acid

RCC: Renal Cell Carcinoma

SITC: Society for Immunotherapy of Cancer

